Interim results demonstrate a favourable safety and tolerability profile for RESP-X in ongoing Phase I clinical trial
Alderley Park, Cheshire U.K. Infex Therapeutics, a leading anti-infectives…
Infex strengthens Board with appointment of Professor Colm Leonard as Non-Executive Director
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Antimicrobial discovery and drug development - RSC Podcast
How do we develop drugs like antibiotics? How long does it take for such a drug…
Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa
First subject dosed in Phase I study to evaluate safety and tolerability of…
Infex Awarded Biomedical Catalyst Grant For COV-X Project
Alderley Park, Cheshire, U.K - Infex Therapeutics, a leading anti-infectives…
COVID-19 Pandemic Triggers Upsurge in MBL Infections
New research has discovered that the ongoing COVID-19 pandemic has triggered a…